By now, I think it’s safe to say that Jim Cramer was dead wrong.
And I was right on the money.
Here’s the thing. I remember very clearly the day that Amazon.com Inc. (AMZN) crossed the $1,000 mark on May 31, 2017.
Cramer, the host of CNBC’s Mad Money looked at the price and slammed it. He said that “psychologically” $1,000 is a lot to pay for a stock he felt was getting ahead of itself.
As the saying goes, that was then and this is now.
No doubt, the tech leader hit a rough patch late last year with the rest of the market. And it has come under fire recently as part of the Big Tech backlash.
Yet, below-expected earnings reports for Q2 and Q3 of this year could only pull Amazon down into the $1,700 range, still far above what Cramer was worrying about.
Not only that, but the “King of E-commerce” is well positioned for another historic moment. It’s roughly 15% away from having a $1 trillion market cap, and most of that would just be regaining lost ground
And today, you’ll see why I still firmly believe the stock will hit at least $3,000 a share – and likely much, much more than that…
Roku Inc. (ROKU) has been having some good days in early November, and it’s perfectly positioned to capitalize on the rise of streaming; but its future is not necessarily certain. The streaming platform has had to deal with some price instability after its quick rise, and now the question of whether its freemium pricing model can meet consumer demand is surfacing. Meanwhile, the digital streaming market is full of tough competitors – and there are two more prominent than ever, ready to hash it out. This is one battle you need to watch closely, as the winner could spell out huge profits for whomever latches on now. Click here to watch.
You could forgive drug and biotech executives for having a bad case of target fixation.
After all, they do work in a field that is filled with time-consuming and expensive headaches.
Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.
The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.
With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.
And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.
It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months…